A New Approach to Treating
Global Infectious Diseases

Scientific Advisory Board

Vijay Pande

Vijay Pande, PhD

Dr. Pande is currently a General Partner at Andreessen Horowitz. Dr. Pande is also a Professor of Chemistry and (by courtesy) of Structural Biology and of Computer Science at Stanford University, where he also served as the Director of the Program in Biophysics. Dr. Pande's research centered on the development and application of novel grid computing simulation techniques to address problems in chemical biology. In particular, he pioneered novel distributed computing methodology to break fundamental barriers in the simulation of kinetics and thermodynamics of proteins and nucleic acids. His research also included novel computational methods for drug design, especially in the areas of protein misfolding and related diseases such as Alzheimer's Disease.

As Director of the Folding@Home project (http://folding.stanford.edu), Dr. Pande has, for the first time, directly simulated protein folding dynamics with quantitative comparisons with experiment, often considered a "holy grail" of computational biology.

Dr. Pande currently sits on the scientific advisory boards of numerous biotechnology companies, including Counsyl, Schrodinger, and, previously, OpenEye Scientific. Dr. Pande has consulted for numerous pharmaceutical companies, including serving as a Distinguished Visiting Professor of Computer Science at Andreesen Horrowitz. Dr. Pande received his bachelor's degree in Physics from Princeton University, and holds his Ph.D. in Physics from MIT.


Bogdan Olenyuk, PhD

Dr. Bogdan Olenyuk, Ph.D., is a professor at the Proteogenomics Research Institute for Systems Medicine. Previously, Dr. Olenyuk was an Assistant Professor of Pharmacology and Pharmaceutical Sciences at the School of Pharmacy, University of Southern California. Dr. Olenyuk's research focuses at the interface of chemistry, biology, and genetics to inform the design and development of mechanism-based anticancer drugs. In particular, Dr. Olenyuk has developed small molecule inhibitors that effectively downregulate the expression of hypoxia-inducible genes, including VEGF, its receptors and genes whose protein products are involved in the growth and metastatic spread of solid tumors.

Dr. Olenyuk has received the National Science Foundation Career Award, and his pioneering research is funded by the NIH, the US Department of Defense Congressionally Directed Medical Research Programs, and the American Cancer Society.

Prior to joining USC, Dr. Olenyuk was a Chemistry and Biochemistry Faculty member at the University of Arizona, where he further served as the Comprehensive Member of the Leon Levy Cancer Center in the UA School of Medicine. Prior to Arizona, Dr. Olenyuk spent time as an NIH Ruth L. Kirschtein Postdoctoral Fellow in the lab of Peter B. Dervan at Caltech. Dr. Olenyuk received his Honors Diploma in Organic Chemistry from Taras Shevchenko National University in Kyiv, and holds a Ph.D. in Chemistry from the University of Utah.